Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report

Pulmonary pleomorphic carcinoma (PPC) has a poor prognosis due to the poor results of treatment with systemic chemotherapy. We report the case of a 73-year-old woman with PPC who showed a favorable response to nivolumab. As first-line treatment for postoperative recurrence, she received carboplatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimoto, Eriko, Yokoi, Takashi, Mikami, Koji, Kanemura, Shingo, Shibata, Eisuke, Horio, Daisuke, Koda, Yuichi, Negi, Yoshiki, Akano, Yumiko, Tada, Akio, Minami, Toshiyuki, Kuribayashi, Kozo, Kijima, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006649/
https://www.ncbi.nlm.nih.gov/pubmed/29928213
http://dx.doi.org/10.1159/000489392
Descripción
Sumario:Pulmonary pleomorphic carcinoma (PPC) has a poor prognosis due to the poor results of treatment with systemic chemotherapy. We report the case of a 73-year-old woman with PPC who showed a favorable response to nivolumab. As first-line treatment for postoperative recurrence, she received carboplatin and nanoparticle albumin-bound paclitaxel. However, 12 months later, a new metastatic lymph node appeared. Nivolumab was administered as second-line treatment, and the patient showed a favorable prolonged response. The effects of treatment of PPC with nivolumab seem promising. The results of a future prospective study are expected to identify indicators for the treatment of PPC.

Ejemplares similares